BioXcel Therapeutics Cash from Financing (TTM) Analysis

BioXcel Therapeutics Inc (BTAI)

2.55 -0.04 (-1.54%) USD | NASDAQ | Apr 18, 16:00

2.55 0.00 (0.00%) After-Hours: 20:00

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2017. Upgrade now.

Date	Value
December 31, 2023	26.52M
September 30, 2023	24.45M
June 30, 2023	54.50M
March 31, 2023	120.39M
December 31, 2022	96.24M
September 30, 2022	96.19M
June 30, 2022	66.21M
March 31, 2022	101.60M
December 31, 2021	102.45M
September 30, 2021	102.68M
June 30, 2021	289.64M
March 31, 2021	188.38M
December 31, 2020	247.36M

Date	Value
September 30, 2020	247.22M
June 30, 2020	78.01M
March 31, 2020	77.66M
December 31, 2019	17.83M
September 30, 2019	17.68M
June 30, 2019	-0.115M
March 31, 2019	-0.062M
December 31, 2018	55.53M
September 30, 2018	56.82M
June 30, 2018	57.59M
March 31, 2018	58.24M
December 31, 2017	3.083M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

-0.115M

Minimum

Jun 2019

289.64M

Maximum

Jun 2021

102.89M

Average

96.19M

Median

Sep 2022

Cash from Financing (TTM) Benchmarks